Search clinical trials for: MK-7622

Total 1731 results

Mindera Health

Not yet recruiting

Subjects Through the Application of the Mindera Kit Part 2 (STAMP-2)

Psoriasis
Merck Sharp & Dohme LLC

Recruiting

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection

United States, Mexico, Russian Federation, South Africa, Thailand
Imago BioSciences, Inc., a subsidiary of Merck...

Active, not recruiting

Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

Primary Myelofibrosis | Thrombocythemia, Essential

United States, Australia, Hong Kong, Germany, Italy, New Zealand, United Kingdom
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

Poland, United States, Argentina, Chile, Japan, Australia, France, New Zealand, South Africa, Turkey
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Breast Cancer
Organon and Co

Completed

A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

Hypogonadotropic Hypogonadism | Hypogonadism
Merck Sharp & Dohme LLC

Active, not recruiting

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Urothelial Carcinoma

Australia, United States, Chile, Denmark, Israel, Korea, Republic of, Spain
Loyola University
Merck Sharp & Dohme LLC

Completed

Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer (MK-0752)

Breast Cancer

United States
Sahlgrenska University Hospital, Sweden

Completed

The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease

Parkinson Disease

Sweden
Vedic Lifesciences Pvt. Ltd.

Completed

A Study to Evaluate Efficacy of Different Natural Ingredients in Improving Gut Health in Adults With Leaky Gut.

Gut Health

India
Johns Hopkins University
National Institute on Aging (NIA)

Withdrawn

Tau Tracer Comparison in Healthy Controls and Alzheimer's Disease Patients

Healthy | Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Terminated

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Advanced Solid Tumors

France, Germany, Spain, United Kingdom
Sarcoma Alliance for Research through Collaboration
Merck Sharp & Dohme LLC

Completed

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Soft Tissue Sarcoma | Bone Sarcoma

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer (PANACEA)

Metastatic Breast Cancer

France, Austria, Belgium, Australia, Italy
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)

Hepatitis C
ALK-Abelló A/S

Completed

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)

Rhinitis, Allergic | Conjunctivitis
Merck Sharp & Dohme LLC

Completed

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Neuromuscular Blockade
MedSIR

Terminated

Checkpoint Blockade in COVID-19 Pandemic (COPERNICO)

COVID-19 | Pneumonia, Viral

Spain
PMV Pharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Metastatic Cancer | Advanced Solid Tumor | Endometrial Cancer | Metastatic Solid Tumor | Other Cancer | Advanced Malignant Neoplasm | Locally Advanced

United States, Spain, Korea, Republic of, Singapore, Australia, France, Germany, Italy, United Kingdom
Institut de Recherches Internationales Servier
Merck Sharp & Dohme LLC

Recruiting

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma

Astrocytoma

United States
Leiden University Medical Center
Takeda; Netherlands Brain Foundation

Recruiting

Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury (CIAO@TBI)

Traumatic Brain Injury | Trauma, Head

Netherlands
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Carcinoma, Renal Cell

Poland, Australia, Japan, United States, Korea, Republic of, Taiwan, China, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Romani... and more
National Cancer Center, Japan
Merck Sharp & Dohme LLC

Recruiting

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Italy, Brazil, Chile, France, Germany, Korea, Republic of, Norway, Singapore, Switzerland, Taiwan, Thailand, Turkey
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)

Carcinoma, Renal Cell

United States, Australia, Belgium, Greece, Ireland, Israel, Netherlands, Russian Federation, United Kingdom
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC

Completed

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Brain Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)

Solid Tumor
Merck Sharp & Dohme LLC

Terminated

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)

Acute Myelogenous Leukemia (AML)
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Urovant Sciences GmbH

Completed

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Overactive Bladder

United States, Poland
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)

Carcinoma, Renal Cell

United States
OncoImmune, Inc.
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)

Non-Small-Cell Lung Cancer
Nasser Hanna, M.D.
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Terminated

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Genital Neoplasms, Female | Testicular Neoplasms | Genital Neoplasms, Male | Ovarian Neoplasms | Mediastinal Neoplasms | Germ Cell Neoplasms | Non Seminomatous Germ Cell Tumors

United States
PETHEMA Foundation
Merck Sharp & Dohme LLC; Adknoma Health Research

Completed

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Multiple Myeloma

Spain
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

MSI Positive Colorectal Cancer | MSI Negative Colorectal Cancer | MSI Positive Non-Colorectal Cancers

United States
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)

Hepatitis C Infection
National Institute of Mental Health (NIMH)

Completed

Antidepressant Effects of NR2B in Major Depression

Major Depression

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

Coronavirus Disease (COVID-19)

Canada, France, Italy, Mexico, Philippines, Russian Federation, Spain, Ukraine, United Kingdom, United States, Argentina, Brazil, Chile, Colombia, Egypt, Germany, Guatemala, Israel, Japan, Poland, South Africa, Sweden, Taiwan
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) (PRIMUS)

Metastatic Squamous Non-small Cell Lung Cancer

Germany
Erasmus Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab (RESPONDER)

Biomarkers | Transitional Cell Carcinoma of the Bladder

Netherlands
Urovant Sciences GmbH

Completed

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Fox Chase Cancer Center
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors

United States
National Cancer Institute (NCI)

Completed

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer (MTC)

United States
Center Trials & Treatment

No longer available

Expanded Access for Pembrolizumab (MK-3475)

Glioblastoma Multiforme | Melanoma (Skin) | Melanoma Recurrent | Glioma of Brain | Glioblastoma by Gene Expression Profile

Hong Kong, Belarus, Tajikistan, Uzbekistan

Search clinical trials for: MK-7622

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations